Polyneuron Pharmaceuticals

In other news

• April 23, 2021 General
  Polyneuron and University of Basel awarded grant of CHF 1.2 M to advance novel treatments to support ABO-Incompatible transplants

  Polyneuron is proud to announce that – together with the… [read on]

• October 7, 2020 Uncategorized
  Polyneuron appoints Aled Williams as chief business officer

  We are extremely pleased to welcome Aled Williams to Polyneuron… [read on]

• September 16, 2020 General
  Polyneuron extends Series A to CHF 36.5 million

  Polyneuron announces a CHF 14 million extension of the Series… [read on]

• June 5, 2020 General
  Polyneuron's PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy

  Polyneuron is proud to announce that the U.S. Food and… [read on]

• April 27, 2020 General
  Polyneuron receives approval to begin clinical study with PN-1007 in anti-MAG neuropathy

  We are very proud to have received our… [read on]

• April 7, 2020 General
  Polyneuron announces appointment of chief medical officer

  We are extremely pleased to welcome Dr Debra Barker to… [read on]

• September 5, 2019 General
  Polyneuron annouces appointment of new Chairman

  Polyneuron announces the appointment of Ben Machielse as Chairman of… [read on]

• March 28, 2019 Financing
  Polyneuron raises CHF 22.5 million in a major Series A financing

  Polyneuron raises CHF 22.5 million in an oversubscribed… [read on]